Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from January 30, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 30, 2026 — +0.5% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$105.00 – $110.00Entry zone — fair-value band

$108.60Published — price the day we called it

$119.46Target — the price the thesis aimed for

$125.14Peak — highest point inside the window, not a realized return

$109.18Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 5 days.

At window close

+0.5%

realized, from the publication price to the last close inside the window

Peak gain

+15.2%

peak, from the publication price — not a realized return

S&P 500, same window

+4.1%

SPY over the identical days, dividend-adjusted

Window close

$109.18

last close inside the window, ended April 30, 2026

Peak price

$125.14

peak on February 25, 2026 — not a realized return

Days to target

The thesis — published January 30, 2026

Predicted growth

+10%

over the measurement window

Target price

$119.46

the price the thesis aimed for

Entry zone

$105.00 – $110.00

the fair-value band we waited for

Price at publication

$108.60

published January 30, 2026

Confidence

65%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is a defensive healthcare stock with an upcoming earnings report on Feb 3 that could change how investors view it. The price has been weak but looks steadier; if the report is clean, the shares might bounce in the next few months as people shift into safer stocks. But drug-company updates and guidance can move shares fast, so wait for the market reaction and keep position size small if expectations fall.

Primary drivers

Earnings can lower uncertainty and reset expectations
Investors move to defensive stocks during market stress
Big pharma trading means easier buying and selling
Company pipeline updates and guidance can swing the stock

How it played out

MRK: target reached in 5 days

Lyra published MRK at $108.60 on 2026-01-30, with a short-term thesis for 10% growth. The thesis pointed to the Feb. 3 earnings report, a steadier price after weakness, possible defensive demand, big-pharma liquidity, and the risk that pipeline updates or guidance could move the stock quickly.

Inside the window, MRK reached the $119.46 target in 5 days. It later peaked at $125.14 on 2026-02-25, a 15.2% gain. By 2026-04-30 it ended at $109.18. The published thesis played out, but the move did not hold near the peak through the close.

What happened during the window

On Feb. 3, 2026, Merck reported fourth-quarter 2025 revenue of $16.4 billion and adjusted earnings per share of $2.04. It also gave 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15.

Merck’s outlook for 2026 comes in below expectations as pipeline faces make-or-break year

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals